BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9279354)

  • 1. [A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist].
    Hisamatsu K; Iwamori S; Minami K; Tanabe K; Ota K; Akiyama H
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1327-30. PubMed ID: 9279354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of LH-RH agonist for bone metastases of breast cancer--report of a case].
    Kudoh S; Kawamura H; Suzuki Y; Matsuzaki M; Nishina M; Tsukamoto M
    Gan To Kagaku Ryoho; 1996 May; 23(6):787-90. PubMed ID: 8645031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
    Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
    Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy].
    Baba S; Oji Y; Teramoto M; Kawabata K; Saito A
    Gan To Kagaku Ryoho; 2009 Nov; 36(11):1905-6. PubMed ID: 19920398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adjuvant chemotherapy of premenopausal breast cancer with LH-RH analogue for ovarian protection--a case report].
    Asaga S; Ando J; Arai T; Fujii H
    Gan To Kagaku Ryoho; 2005 Jul; 32(7):1069-72. PubMed ID: 16044976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Endocrine therapy for advanced or recurrent breast cancer].
    Sonoo H; Kurebayashi J
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):909-16. PubMed ID: 11478139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of premenopausal patients with advanced or recurrent breast cancer by chemical ablation].
    Sun Q; Huang HY; Zhou YD; Mao F; Yang YQ; Xing Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Feb; 25(1):60-2. PubMed ID: 12905610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of goserelin in the treatment of breast cancer.
    Rody A; Loibl S; von Minckwitz G; Kaufmann M
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current status of adjuvant endocrine therapy for hormone responsive breast cancer].
    Ikeda T; Jinno H; Masamura S; Matsui A; Tajima G; Hohjoh T; Tokura H; Mitsui Y; Asaga S; Muto T; Fujiwara K; Kitajima M
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):902-8. PubMed ID: 11478138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives.
    Del Mastro L; Levaggi A; Giraudi S; Pronzato P
    Cancer Treat Rev; 2011 May; 37(3):208-11. PubMed ID: 20724078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of GnRH analogues in early and advanced breast carcinomas].
    Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
    Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
    Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
    J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer].
    Sano M; Makino H
    Nihon Rinsho; 2000 Apr; 58 Suppl():328-33. PubMed ID: 11026014
    [No Abstract]   [Full Text] [Related]  

  • 17. Aromatase inhibitor withdrawal response in metastatic breast cancer.
    Cigler T; Goss PE
    J Clin Oncol; 2006 Apr; 24(12):1955-6. PubMed ID: 16622274
    [No Abstract]   [Full Text] [Related]  

  • 18. [Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
    Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):495-508. PubMed ID: 7887641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!
    Samur M; Bozcuk HS
    J Clin Oncol; 2003 Jun; 21(12):2444; author reply 2445-7. PubMed ID: 12805349
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
    Nishimura R; Anan K; Yamamoto Y; Higaki K; Tanaka M; Shibuta K; Sagara Y; Ohno S; Tsuyuki S; Mase T; Teramukai S
    Oncol Rep; 2013 May; 29(5):1707-13. PubMed ID: 23446822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.